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Orbital mesenchymal chondrosarcoma is a very uncommon lesion of the bone and extraskeletal tissue. To our knowledge,
approximately 30 cases have been described. We present the case of a 52-year-old male who presented with a history of progressive
proptosis and chemosis of the right eye caused by an orbital tumor. He underwent exenteration of the right orbit, and the
histologicalexaminationrevealedamesenchymalorbitalchondrosarcoma.Thispaperattemptstodescribearareentitythatshould
be considered in the diﬀerential diagnosis of calciﬁed orbital lesions, especially in young adults. Complete removal of the tumor is
the mainstay of treatment, but adjuvant radiation therapy and chemotherapy should be considered.
1.Introduction
Mesenchymal chondrosarcoma of the head and neck is
an uncommon tumor with potential for exhibiting highly
aggressive behavior. This lesion is a malignant small round
cell neoplasm with focal cartilaginous diﬀerentiation, often
withapericytomatousvascularpattern.Itrepresentsapprox-
imately 1% of all chondrosarcomas [1] and approximately
0.1% of all head and neck neoplasms [2, 3]. In the head
and neck region, it presents with a predilection for the
maxillofacial skeleton, where it has been reported to occur
in particular in the mandible and maxilla [4].
It is usually seen in younger age group compared to
conventional chondrosarcomas [3].
There are approximately 30 cases described in the
literature. The aim of this paper is to report a case of
mesenchymal chondrosarcoma of the orbit.
2. Case Presentation
A 52-year-old man, without any past medical illness, pre-
sented with a 12-month history of progressive proptosis
of the right eye. Physical examination revealed a decreased
right visual acuity, inferior displacement of the globe,
severeconjunctivalchemosis,andreducedcornealsensitivity
(Figure 1). No abnormality of the left eye was detected. An
incisional biopsy was performed at a diﬀerent institution,
and the pathology report demonstrated a fusocellular neo-
plasm with hemangiopericytoma pattern, also compatible
with monophasic synovial sarcoma. Computed tomography
(CT) and magnetic resonance imaging (MRI) scans revealed
a well-deﬁned right intrasonic mass, measuring 5.3 × 4.6 ×
3.6cm, with ocular globe displacement but without involve-
ment of the temporal fossa (Figure 2). Upon admission, the
patient had a Karnofsky score of 90% and was classiﬁed as
grade zero according to the status of the Eastern Cooperative
Oncology Group (ECOG).
Based on this diagnosis, a right lateral orbital exenter-
ation with excision of the mass by a craniofacial approach
w a sp e r f o r m e d .W ef o u n dam a s st h a tm e a s u r e d7× 8cm
with sphenoidal ﬁssure obliteration and destruction of the
roof and lateral wall of the orbit. Based on these ﬁndings, the
lesion was resected, and we performed an orbital roof plasty
with cyanoacrylate (Figure 3). There were no postopera-
tive complications. Deﬁnitive histopathological examination
revealed a mesenchymal chondrosarcoma located in the
orbital soft tissue, with temporal muscle and zygomatic bone
inﬁltration and a 5mm bone margin. The posterior edge of2 Case Reports in Medicine
Figure 1: Patient at the onset with inferior displacement of the
globe and severe conjunctival chemosis.
Figure 2: Axial and coronal MRI image showing a right intraconic
and extrasonic mass with ocular globe displacement and temporal
muscle and zygomatic bone inﬁltration.
the ocular globe, the globe itself, and the optic nerve did not
show evidence of the neoplasm (Figure 4).
The patient was advised adjuvant chemotherapy and
radiotherapy. He received a total of 66Gy of external
radiotherapy to the temporozygomatic region, showing no
signs of toxicity or infection. He is currently on a regimen of
vincristine, adriamycin, and cyclophosphamide alternating
with ifosfamide and etoposide (VAC/IE), which is used in
the treatment of patients with Ewing’s Sarcoma. Currently,
the patient is alive and without evidence of disease.
3. Discussion
The ﬁrst case of mesenchymal chondrosarcoma (MCS)
was described by Lichtenstein and Bernstein in 1959 [5].
Approximately10%occurintheheadandneckregion,being
the maxillomandibulofacial skeleton the site in the head
and neck where mesenchymal chondrosarcomas are most
commonly encountered. Less commonly encountered sites
in the head and neck include the sinonasal tract, orbit, and
thyroid gland [1]. Our case is one of the approximately 30
cases already reported with localization in the orbit. This
tumortendstoaﬀectpatientsintheirsecondorthirddecades
of life, with a female preponderance [1, 6], something
important to notice given that the patient herein described
Figure 3: Orbitozygomatic approach. Tumoral resection and
reconstruction with cyanoacrylate.
is a 52-year-old male, in contrast with the typical sex and age
of onset.
Clinically,thesetumorstendtopresentwithcompression
of the ocular globe resulting in progressive proptosis and/or
visual abnormalities, such as diplopia or reduction in visual
acuity. The radiological examination is relevant to help
establish the diagnosis. CT scans usually reveal presence of
foci of calciﬁcation in the lesion. MRI scans are helpful
to delimitate the lesion margins [7]. Our patient presented
these clinical and radiological ﬁndings, in accordance with
previous reports in the literature.
Histologically, this tumour exhibits a biomorphic
appearance of undiﬀerentiated mesenchymal cells with
islands of mature hyaline cartilage [8]. Immunohistochemi-
calanalysisoftenrevealspositivityforvimentin,S100protein
and CD99; meanwhile, actin, cytokeratin, and EMA are
typically negative [9, 10]. The diﬀerential diagnosis of orbital
MCS includes hemangiopericytoma, myxochondrosarcoma,
osteogenicsarcoma,andosteochondromaasprimarytumors
and lymphoma, neuroblastoma, synovial cell sarcoma, and
chondrosarcoma as tumors aﬀecting the orbit secondarily
(direct invasion or metastasis) [11]. This case presented
no diﬃculty in the histopathological diagnosis since it
showed a characteristic morphological pattern composed of
round cells with an abrupt transition to well-diﬀerentiated
hyaline cartilage and a hemangiopericytoma-like vascular
pattern. The immunohistochemical analysis was positive for
S100 protein and negative for cytokeratin and actin, which
are some of the immunohistochemical characteristics often
described for this type of tumors. In this case, hemangioper-
icytoma was considered the principal diﬀerential diagnosis.
Surgical resection with wide margins is known as the
most eﬀective treatment modality for chondrosarcoma [3].
Zakkak et al. reviewed various treatment modalities in the
maxilla and mandible and found that the best outcome
was after radical surgery [12]. The overall low incidence of
regional metastasis may suggest that neck dissection is not
indicated.Case Reports in Medicine 3
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Figure 4: (a) Macroscopic view of the resected specimen. (b) Microphotography (4x) of the neoplasm showing a hemangiopericytoma-like
vascular pattern, with proliferation of small, round cells with clear cytoplasm. (c) Closer view of the previous microphotography (40x),
showing the small round cells surrounding the vessels. (d) Microphotography (40x) showing the transition between well diﬀerentiated
cartilage and small cell areas.
Radiotherapy might play a role when accompanied by
surgery although some believe MCS to be a radioresistant
tumor [3, 13]. Some authors report the use of preoperative
radiation therapy to reduce tumor bulk prior to radical
resection, with the hope of reducing extension in continuity
or by micrometastasis, but it does not change the preoper-
ative approach. Postoperative radiotherapy does not show a
statistically signiﬁcant proof of better prognosis even when
there is evidence that demonstrates trend toward increased
survival [14].
Chemotherapy has a limited role in chondrosarcoma
and should be used as an adjuvant therapy in cases with
aggressive behavior with potential metastasis, rapid local
recurrence,andhigh-gradelesions[2,3,13].Thispatientwas
advised the same chemotherapy regimen as used for Ewing’s
sarcoma. The standard neoadjuvant/adjuvant chemotherapy
backbone consists of vincristine, dactinomycin, cyclophos-
phamide, and doxorubicin (VACD). Since then, a number
of studies have sought to improve on that standard, using
chemotherapy with VACD either alone or alternating with
ifosfamide and etoposide (VACD-IE), the latter signiﬁcantly
improved 5-year disease-free survival (DFS) (69% versus
54%, P = .005), and mesenchymal chondrosarcoma could
be treated as per Ewing’s sarcoma [15].
There are numerous active signaling pathways that have
been described in human chondrosarcoma, trying to suggest
potential molecular targets for directed chemotherapy. One
of these is a pathway dependent on phosphoinositide-3
kinase and MEK-extracellular signal-regulated kinase (ERK)
signaling. Additionally, chondrosarcoma cell proliferation
and degradation is dependent on peroxisome proliferator-
activated receptor-gamma (PPAR-c) activity, with a loss of
PPAR-c expression and associated apoptosis in high-grade
tumors. Targeting these pathways may improve control of
cranial chondrosarcoma and decrease the need of recurrent
operations [16].
TheprognosisofpatientswithMCSisextremelyvariable,
ranging from complete tumor response and long-term
survival, to rapid local tumor progression with widespread
metastasis. The mesenchymal histology alone carries a
nearly 10-fold increase in 5-year mortality. The overall
5- and 10-year survival for patients with mesenchymal
chondrosarcoma,whenconsideringallsites,is55%and27%,
respectively. It has been postulated that earlier detection and4 Case Reports in Medicine
diagnosisoflesionsintheheadandneckmayinpartaccount
for improved survival for mesenchymal chondrosarcoma
located in the head and neck [1, 17].
4. Conclusion
Orbital mesenchymal chondrosarcoma is a rare entity and
should be considered in the diﬀerential diagnosis of calciﬁed
orbital lesions, especially in young adults. Complete removal
of the tumor, either by orbital resection or exenteration, is
the mainstay of treatment. Adjuvant radiation therapy and
chemotherapyshouldbeconsidered,duetothehistologically
aggressive nature of the tumor.
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